Business
Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
BOSTON, July 01, 2025--Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs. Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures a
About this update from W.r. Berkley Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":9963,"height":3512,"url":"https://media.zenfs.com/en/business-wire.com/a02ae87edad329594537b917a0a3059a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kqGxOZbBhVmjS0iiMnplbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a02ae87edad329594537b917a0a3059a","width":960,"height":338},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/whFlOcHm8FSMGm8QjWA.2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a02ae87edad329594537b917a0a3059a","width":1200,"height":423}},"lazy":false},{"type":"text","content":"Oversubscribed Series A financing led by Cerberus Ventures, with participation from multiple new and existing investors, totals $33 million","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Syntis also awarded up to $5 million in non-dilutive grants from NIH","length":68,"tagName":"p","attribs":{}},{"type":"text","content":"Capital supports SYNT™ platform advancement, including lead SYNT-101 obesity program and SYNT-202 for rare pediatric disorder homocystinuria","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"Chenny Zhang of Cerberus Ventures and Michael Nannizzi of W. R. Berkley join Board of Directors","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, July 01, 2025--(BUSINESS WIRE)--Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs. Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures also participated. Syntis has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supporting the advancement of its SYNT™ (SYNthetic Tissue-lining) platform.","le...